OSR Holdings(OSRH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OSRH OSR Holdings

Closed 12-18 16:00:00 EST

0.5728

+0.0305

+5.62%

盘后0.5726

-0.0002-0.03%

18:48 EST

High0.6200	Low0.5450	Vol359.96K
Open0.5456	D1 Closing0.5423	Amplitude13.83%
Mkt Cap14.71M	Tradable Cap1.34M	Total Shares25.67M
T/O209.15K	T/O Rate15.36%	Tradable Shares2.34M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OSRH","market":"US","secType":"STK","nameCN":"OSR Holdings","latestPrice":0.5728,"timestamp":1766091600000,"preClose":0.5423,"halted":0,"volume":359958,"hourTrading":{"tag":"盘后","latestPrice":0.5726,"preClose":0.5728,"latestTime":"18:48 EST","volume":635,"amount":365.9416,"timestamp":1766101687617},"delay":0,"floatShares":2342900,"shares":25672788,"eps":-0.849765,"marketStatus":"Closed","change":0.0305,"latestTime":"12-18 16:00:00 EST","open":0.5456,"high":0.62,"low":0.545,"amount":209145.9647904,"amplitude":0.1383,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.849765,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766134800000},"marketStatusCode":5,"adr":0,"listingDate":1679025600000,"exchange":"NASDAQ","adjPreClose":0.5423,"preHourTrading":{"tag":"盘前","latestPrice":0.547,"preClose":0.5423,"latestTime":"09:28 EST","volume":376,"amount":209.34811440000001,"timestamp":1766068102728},"postHourTrading":{"tag":"盘后","latestPrice":0.5726,"preClose":0.5728,"latestTime":"18:48 EST","volume":635,"amount":365.9416,"timestamp":1766101687617},"volumeRatio":1.283492},"requestUrl":"/m/hq/s/OSRH/tweets","defaultTab":"tweets","newsList":[{"id":"2589783230","title":"Emerging Growth Research Reaffirms Buy on OSR Holdings With $10 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2589783230","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589783230?lang=en_us&edition=fundamental","pubTime":"2025-12-05 04:19","pubTimestamp":1764879594,"startTime":"0","endTime":"0","summary":"Emerging Growth Research has released a flash report on OSR Holdings Inc. , reaffirming its Buy-Emerging rating and setting a 12-month price target of $10.00, representing a potential 1,487% upside from the company's recent closing price. The report highlights a significant non-binding licensing term sheet between OSR Holdings and BCM Europe AG, valued at $815 million, for the global development and commercialization of OSRH's oral T-cell immunotherapy program, VXM01. The agreement, which includes an expected $20 million upfront payment in 2026 and subsequent milestone payments, is seen as a major validation of OSR Holdings' strategy and management. The research also notes increased likelihood of deal completion and strong cash flow prospects beginning in 2026, positioning OSRH for further potential growth.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gener","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL4SmJC2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSRH","BK4139"],"gpt_icon":0},{"id":"2588517500","title":"Osr Holdings Inc - Vaximm Ag Shortens Exclusivity Period With Bcm Europe to Three Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2588517500","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588517500?lang=en_us&edition=fundamental","pubTime":"2025-12-02 22:55","pubTimestamp":1764687303,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X80GK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OSRH"],"gpt_icon":0},{"id":"2588796051","title":"Vaximm AG Shortens Exclusivity Period With BCM Europe for Cancer Immunotherapy Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2588796051","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588796051?lang=en_us&edition=fundamental","pubTime":"2025-12-02 22:54","pubTimestamp":1764687257,"startTime":"0","endTime":"0","summary":"Vaximm AG, an OSR Holdings Subsidiary, Updates Term Sheet with BCM Europe to Accelerate VXM01 Licensing Deal. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSR Holdings Inc. published the original content used to generate this news brief via PR Newswire  on December 02, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL6vG3kD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSRH","BK4139"],"gpt_icon":0},{"id":"2588770422","title":"OSR Holdings to Present Corporate Overview at Emerging Growth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2588770422","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588770422?lang=en_us&edition=fundamental","pubTime":"2025-12-02 04:02","pubTimestamp":1764619342,"startTime":"0","endTime":"0","summary":"OSR Holdings Inc. will present at the Emerging Growth Conference on December 10, 2025. The virtual presentation, scheduled to begin at 9:05 a.m. ET, will offer an updated overview of the company's diversified healthcare platforms and strategic growth initiatives. Interested attendees are encouraged to register in advance, and an archived webcast will be available after the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSR Holdings Inc. published the original content used to generate this news brief via PR Newswire  on December 01, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDLbJ4p8h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSRH","BK4139"],"gpt_icon":0},{"id":"2586777294","title":"OSR Holdings’ Vaximm AG Enters Licensing Term Sheet","url":"https://stock-news.laohu8.com/highlight/detail?id=2586777294","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586777294?lang=en_us&edition=fundamental","pubTime":"2025-11-26 00:17","pubTimestamp":1764087455,"startTime":"0","endTime":"0","summary":"OSR Holdings ( ($OSRH) ) just unveiled an announcement. On November 21, 2025, OSR Holdings‘ subsidiary, Vaximm AG, entered into a non-binding globa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/osr-holdings-vaximm-ag-enters-licensing-term-sheet?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/osr-holdings-vaximm-ag-enters-licensing-term-sheet?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OSRH","BK4139","BK4210","AG"],"gpt_icon":0},{"id":"2586472276","title":"Vaximm AG Enters $835M License Term Sheet With BCM Europe for Cancer Immunotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2586472276","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586472276?lang=en_us&edition=fundamental","pubTime":"2025-11-25 23:56","pubTimestamp":1764086219,"startTime":"0","endTime":"0","summary":"Vaximm AG, an OSR Holdings Subsidiary, Signs Term Sheet With BCM Europe for Potential $20M Upfront VXM01 License and Up to $815M in Milestones. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSR Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 25, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL4nnNpP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSRH"],"gpt_icon":0},{"id":"2586397444","title":"OSR Holdings Reports High Accuracy for Woori IO Noninvasive Glucose Monitor in Pilot Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2586397444","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586397444?lang=en_us&edition=fundamental","pubTime":"2025-11-25 14:43","pubTimestamp":1764053007,"startTime":"0","endTime":"0","summary":"OSR Holdings Inc. has announced the results of a company-sponsored pilot study evaluating the performance of the Glucheck noninvasive blood glucose measurement system, developed by its subsidiary Woori IO in collaboration with Korea University Guro Hospital. The study, conducted from May 9 to September 12, 2023, assessed the accuracy, stability, and usability of the Glucheck system in both mouse-type and stick-type models against a standard laboratory reference device. The findings, based on a Clinical Study Report completed in 2023, demonstrated that the system achieved accuracy and reliability comparable to leading commercially available minimally invasive continuous glucose monitors. The results have already been presented by the company. Building on this data, Woori IO and Samsung are conducting a new proof-of-concept study, and a formal MFDS-compliant clinical trial is planned for the first half of 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL8b9YH3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSRH","BK4139"],"gpt_icon":0},{"id":"2585494541","title":"OSR Holdings’ Vaximm AG enters non-binding term sheet with BCM Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2585494541","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585494541?lang=en_us&edition=fundamental","pubTime":"2025-11-21 22:25","pubTimestamp":1763735117,"startTime":"0","endTime":"0","summary":"OSR Holdings (OSRH) announced that Vaximm AG, an OSR company, has entered into a non-binding term sheet with BCM Europe AG, a Swiss-based life scie...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/osr-holdings-vaximm-ag-enters-non-binding-term-sheet-with-bcm-europe-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/osr-holdings-vaximm-ag-enters-non-binding-term-sheet-with-bcm-europe-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","OSRH","BK4210","AG","BCM"],"gpt_icon":0},{"id":"2585149886","title":"Vaximm Ag, an Osr Company, Enters Term Sheet With Bcm Europe for Potential Vxm01 License With $20M Upfront and up to $815M in Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2585149886","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585149886?lang=en_us&edition=fundamental","pubTime":"2025-11-21 22:23","pubTimestamp":1763735005,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nFWN3WX0LO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OSRH","BK4139"],"gpt_icon":0},{"id":"2585074146","title":"Vaximm AG Enters $20M Term Sheet for VXM01 License Negotiations","url":"https://stock-news.laohu8.com/highlight/detail?id=2585074146","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585074146?lang=en_us&edition=fundamental","pubTime":"2025-11-21 22:20","pubTimestamp":1763734817,"startTime":"0","endTime":"0","summary":"Vaximm AG, a subsidiary of OSR Holdings Inc., has entered into a non-binding term sheet with BCM Europe AG for a potential exclusive global licensing agreement for its oral cancer immunotherapy platform, VXM01. The proposed deal includes a $20 million upfront payment, up to $815 million in milestone payments, and a royalty pass-through structure.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSR Holdings Inc. published the original content used to generate this news brief via PR Newswire  on November 21, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL8pWmh7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSRH"],"gpt_icon":0},{"id":"2583688866","title":"Vaximm AG Names Scientific Co-Founder Andreas Niethammer as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2583688866","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583688866?lang=en_us&edition=fundamental","pubTime":"2025-11-15 00:11","pubTimestamp":1763136695,"startTime":"0","endTime":"0","summary":"OSR Holdings Inc. announced the appointment of Dr. Andreas Niethammer as Chief Executive Officer of its subsidiary, Vaximm AG. Vaximm, a Swiss-German biotech company, focuses on developing oral T-cell immunotherapies for cancer and is preparing to advance its platform through new strategic collaborations in immuno-oncology.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSR Holdings Inc. published the original content used to generate this news brief via PR Newswire  on November 14, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL2npX1x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSRH","BK4139"],"gpt_icon":0},{"id":"2583863688","title":"Osr Holdings Appoints Scientific Co-Founder DR. Andreas Niethammer as Chief Executive Officer of Vaximm Ag to Lead Next Phase of Immuno-Oncology Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2583863688","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583863688?lang=en_us&edition=fundamental","pubTime":"2025-11-15 00:11","pubTimestamp":1763136678,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nTUA5KZJW1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OSRH","BK4139"],"gpt_icon":0},{"id":"2583589459","title":"OSR Holdings Q3 EPS $(0.10) Beats $(0.12) Estimate, Sales $627.747K Miss $761.000K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583589459","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583589459?lang=en_us&edition=fundamental","pubTime":"2025-11-13 06:30","pubTimestamp":1762986601,"startTime":"0","endTime":"0","summary":"OSR Holdings (NASDAQ:OSRH) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.12) by 16.67 percent. This is a 93.59 percent increase over losses of $(1.56) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48821889/osr-holdings-q3-eps-0-10-beats-0-12-estimate-sales-627-747k-miss-761-000k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"OSR Holdings Q3 EPS $(0.10) Beats $(0.12) Estimate, Sales $627.747K Miss $761.000K Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSRH"],"gpt_icon":0},{"id":"2581275832","title":"OSR Holdings Inc  expected to post a loss of 12 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581275832","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581275832?lang=en_us&edition=fundamental","pubTime":"2025-11-08 06:41","pubTimestamp":1762555263,"startTime":"0","endTime":"0","summary":"OSR Holdings Inc  expected to post a loss of12cents a share - Earnings Preview OSR Holdings Inc OSRH.OQ OSRH.O is expected to  report resultson November 10 (estimated) for the period ending September ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ31K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSRH","BK4139"],"gpt_icon":0},{"id":"2581609634","title":"OSR Holdings Reports High Accuracy in Woori IO Noninvasive Glucose Monitor Pilot Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2581609634","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581609634?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:31","pubTimestamp":1762435890,"startTime":"0","endTime":"0","summary":"OSR Holdings Inc. has announced the results of a company-sponsored pilot study evaluating the Glucheck noninvasive blood glucose measurement system, developed by its subsidiary Woori IO in collaboration with Korea University Guro Hospital. The study, conducted from May 9 to September 12, 2023, assessed the accuracy, stability, and usability of the Glucheck device in 145 participants. The findings, based on a completed Clinical Study Report, indicate that the system demonstrated accuracy and reliability comparable to leading minimally invasive continuous glucose monitors. These results have already been presented by the company. Building on this pilot study, a new proof-of-concept study is currently underway with Samsung, and a formal MFDS-compliant clinical trial is planned for the first half of 2026 at a medical center in Seoul.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely inf","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL1kBH5Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSRH"],"gpt_icon":0},{"id":"2581209503","title":"Osr Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2581209503","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581209503?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:30","pubTimestamp":1762435803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUA4Z11TV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OSRH"],"gpt_icon":0},{"id":"2578092546","title":"OSR Holdings Inc. Files Initial Statement of Beneficial Ownership for Director Reto Kaspar Fierz","url":"https://stock-news.laohu8.com/highlight/detail?id=2578092546","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578092546?lang=en_us&edition=fundamental","pubTime":"2025-10-25 00:58","pubTimestamp":1761325137,"startTime":"0","endTime":"0","summary":"OSR Holdings Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing lists Reto Kaspar Fierz as a Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSR Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 24, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nNDL7T4W7R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSRH","BK4139"],"gpt_icon":0},{"id":"2576866635","title":"Emerging Growth Research Initiates Buy Rating on OSR Holdings with $10 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2576866635","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576866635?lang=en_us&edition=fundamental","pubTime":"2025-10-20 23:40","pubTimestamp":1760974828,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSR Holdings Inc. published the original content used to generate this news brief via Newsfile  on October 20, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDL9Xt4xJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSRH","BK4139"],"gpt_icon":0},{"id":"2575539218","title":"BRIEF-OSR Holdings Signs Definitive Agreement To Acquire Woori IO","url":"https://stock-news.laohu8.com/highlight/detail?id=2575539218","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575539218?lang=en_us&edition=fundamental","pubTime":"2025-10-14 20:33","pubTimestamp":1760445194,"startTime":"0","endTime":"0","summary":"BRIEF-OSR Holdings Signs Definitive Agreement To Acquire Woori IOOct 14 (Reuters) - OSR Holdings Inc OSRH.O:OSR HOLDINGS SIGNS DEFINITIVE AGREEMENT TO ACQUIRE WOORI IO, A PIONEER IN NONINVASIVE GLUCOS","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nTUA72KBLL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSRH"],"gpt_icon":0},{"id":"2575218308","title":"OSR Holdings to Acquire Woori IO, Advancing Noninvasive Glucose Monitoring Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2575218308","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575218308?lang=en_us&edition=fundamental","pubTime":"2025-10-14 20:31","pubTimestamp":1760445076,"startTime":"0","endTime":"0","summary":"OSR Holdings Inc. has executed a definitive agreement to acquire Woori IO Co., Ltd. , a pioneer in noninvasive glucose monitoring technology. Through a comprehensive share exchange, WORIO will become a wholly owned subsidiary of OSR Holdings' Korean affiliate, OSR Holdings Co., Ltd. . WORIO shareholders will receive newly issued OSRK shares valued at approximately $10.5 million in exchange for their WORIO shares. The acquisition brings WORIO's proprietary NIRS-based, needle-free glucose monitoring platform into the OSR Holdings ecosystem, supporting the company's expansion in the global glucose-monitoring market.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSR Holdings Inc. published the original content used to generate this news b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDLT92Pw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSRH"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.osr-holdings.com","stockEarnings":[{"period":"1week","weight":-0.1644},{"period":"1month","weight":0.1177},{"period":"3month","weight":-0.2482},{"period":"6month","weight":-0.6479},{"period":"1year","weight":-0.9518},{"period":"ytd","weight":-0.953}],"compareEarnings":[{"period":"1week","weight":-0.0235},{"period":"1month","weight":0.0086},{"period":"3month","weight":0.0138},{"period":"6month","weight":0.1298},{"period":"1year","weight":0.1111},{"period":"ytd","weight":0.1456}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Bellevue Life Sciences Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company intends to acquire companies in the healthcare industry. Bellevue Life Sciences Acquisition Corp. was founded in 2020 and is based in Bellevue, Washington. Bellevue Life Sciences Acquisition Corp. operates as a subsidiary of Bellevue Global Life Sciences Investors LLC.","exchange":"NASDAQ","name":"OSR Holdings","nameEN":"OSR Holdings"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"OSR Holdings(OSRH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest OSR Holdings(OSRH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"OSR Holdings,OSRH,OSR Holdings股票,OSR Holdings股票老虎,OSR Holdings股票老虎国际,OSR Holdings行情,OSR Holdings股票行情,OSR Holdings股价,OSR Holdings股市,OSR Holdings股票价格,OSR Holdings股票交易,OSR Holdings股票购买,OSR Holdings股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"OSR Holdings(OSRH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest OSR Holdings(OSRH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction